Acta Med. 2005, 48: 57-58

Plasma Concentrations of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Lymphoproliferative Disorders

Lukáš Smoleja, Ctirad Andrýsb, Vladimír Maisnara, Luděk Pourc, Jaroslav Malýa

aCharles University in Prague, Faculty of Medicine in Hradec Králové, 2nd Department of Internal Medicine, Department of Clinical Haematology, Hradec Králové, Czech Republic
bCharles University in Prague, Faculty of Medicine in Hradec Králové, Institute of Clinical Immunology and Allergology, Hradec Králové, Czech Republic
cMasaryk University, Faculty of Medicine, Internal Haematooncology Department, Brno, Czech Republic

Received December 1, 2004
Accepted March 1, 2005

Angiogenesis plays a major role in the development and progression of haematological malignancies. In our study we measured plasma concentrations of key angiogenic activators vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) using comercially available sandwich enzyme-linked immunosorbent assay (ELISA) in 37 patients with lymphoid malignancies and 20 healthy donors. We found a statistically significant increase in bFGF concentrations in patients with B-cell chronic lymphocytic leukemia (B-CLL, n=18) compared to the control group (median 118.8 vs. 9.3 pg/ml, p<0.001). However, we didn’t find any significant difference in VEGF concentrations between B-CLL patients and the control group. There was also no significant increase in bFGF or VEGF in patients with multiple myeloma (n=7) and non-Hodgkin’s lymphoma (n=12). Our pilot study shows that measurement of angiogenic activators in plasma is a feasible and reproducible method of angiogenesis assessment. Larger studies are needed for correlation between serum and plasma concentrations and detailed statistical evaluation including the impact on patients’ survival.


This work was supported in part by grants NR/8076-3 and NR/8373-3 from Ministry of Health of Czech Republic.


9 live references